"label","rationale","id","instanceType","name","description","uuid:ID"
"","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","StudyDesign","Study Design 1","The main design for the study","ced26c71-35a6-4025-8ce9-dd54440fcece"
